Bharat Immunologicals Selected Fundamentals

The Macroaxis Fundamental Analysis lookup allows users to check a given indicator for any equity or select from a set of available indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations. Please check also Equity Screeners to view more equity screening tools

Operating Margin Analysis

Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Bharat Immunologicals 
Operating Margin 
 = 
Operating Income 
Revenue 
X
100 
 = 
(5.13) %

About Operating Margin

A good Operating Margin is required for a company to be able to pay for its fixed costs or pay out its debt which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against firm's competitors.Compare to competition
Based on recorded statements Bharat Immunologicals Biologicals Corp Ltd has Operating Margin of -5.13%. This is much lower than that of the sector, and significantly lower than that of Operating Margin industry, The Operating Margin for all stocks is over 1000% higher than the company.

Bharat Immunologicals Fundamental Drivers Relationships

Bharat Immunologicals Biologicals Corp Ltd is number one stock in price to book category among related companies. It is the top company in revenue category among related companies totaling about  512,000,000  of Revenue per Price to Book.

Did you try this?

Run Global Markets Map Now
   

Global Markets Map

Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Hide  View All  Next  Launch Global Markets Map
Return On Asset(1.69) %
Profit Margin(4.18) %
Operating Margin(5.13) %
Current Valuation862.5 M
Shares Outstanding43.18 M
Price to Earning(28.02) times
Price to Book2.50 times
Price to Sales0.66 times
Revenue1.28 B
Gross Profit119 M
EBITDA(56.51 M)
Net Income(53.46 M)
Cash and Equivalents152.27 M
Cash per Share3.55 times
Total Debt177.56 M
Debt to Equity0.50 times
Current Ratio1.69 times
Earnings Per Share(1.24) times
Market Capitalization1.5 B
Z Score4.8